|
|
Volumn 31, Issue 5, 2004, Pages 249-255
|
|
What interventions are effective for managing peristomal pyoderma gangrenosum?
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALKYLATING AGENT;
ANTIINFLAMMATORY AGENT;
CHLORAMBUCIL;
IMMUNOSUPPRESSIVE AGENT;
INFLIXIMAB;
MONOCLONAL ANTIBODY;
TACROLIMUS;
DEBRIDEMENT;
EVIDENCE BASED MEDICINE;
HUMAN;
METHODOLOGY;
NURSING;
NURSING EVALUATION RESEARCH;
PRACTICE GUIDELINE;
PYODERMA GANGRENOSUM;
RARE DISEASE;
REVIEW;
RISK FACTOR;
SAFETY;
SKIN CARE;
STOMA;
TREATMENT OUTCOME;
UNITED STATES;
ANTI-INFLAMMATORY AGENTS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS, ALKYLATING;
CHLORAMBUCIL;
DEBRIDEMENT;
EVIDENCE-BASED MEDICINE;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
NURSING EVALUATION RESEARCH;
PRACTICE GUIDELINES;
PYODERMA GANGRENOSUM;
RARE DISEASES;
RISK FACTORS;
SAFETY;
SKIN CARE;
STOMAS;
TACROLIMUS;
TREATMENT OUTCOME;
UNITED STATES;
|
|
EID: 33845494144
PISSN: 10715754
EISSN: None
Source Type: Journal
DOI: 10.1097/00152192-200409000-00005 Document Type: Review |
|
Times cited : (5)
|
|
References (48)
|
